Mubasher: Investcorp has acquired Denmark-based Sanos Group, a leading provider of specialised clinical trial services to the global pharmaceutical and biotechnology industry.
Sanos is a global Contract Research Organisation (CRO) providing value-added services to pharma, biotech, and research organisations to help plan and conduct clinical trials, which are a critical part in the development of new drugs and treatments, according to a press release on Monday.
Moreover, it consists of a CRO specialised in osteoarthritis (OA) and a Site Management Organisation (SMO) with a broader indication range focusing on lifestyle and age-related diseases. In addition, it has built a worldwide reputation for its scientific expertise, ability to recruit patients and track record of executing safe and efficient clinical trials.
The global CRO market is estimated to total approximately $50 billion and is growing at approximately 10% per annum.
Head of Private Equity, Europe at Investcorp, Daniel Lopez-Cruz, said; “Sanos has established itself as the partner of choice for pharma and biotech companies looking to conduct clinical trials for osteoarthritis, a condition for which there is currently a very high unmet medical need given the large and growing population of people being affected by it and the fact that there is no cure for it at the moment.”
“Leveraging its strong OA franchise, we believe that Sanos has significant potential for international expansion through new research clinics in the US -the largest market for clinical trials- and other European countries beyond Denmark,” he continued.
Investcorp has an established history of investing in the healthcare sector globally. Sanos’ acquisition is Investcorp’s eleventh investment in the healthcare sector and the third in Europe, following its acquisition of a majority stake in Cambio Healthcare Systems and Acura.